Cel Sci Corporation (CVM)

[lux1]

Very interesting is that the mixture of Leucocyte interleukins are synergic with checkpoint modulators (as the anti CTLA4,anti PD1 and many others)that are largely developed by several pharma and big pharma companies in a very promising multi billions market.
The new immuno-oncology is based on checkpoints modulators, as I already said , Geert should immediately go down this road with pharma partners,because, in any case, Multikine can have a real future ad adjuvant in combo therapies.
Wake-up Geert!